Avior Wealth Management LLC Increases Stake in Novo Nordisk A/S (NYSE:NVO)

Avior Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 13.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,597 shares of the company’s stock after acquiring an additional 2,511 shares during the quarter. Avior Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $1,772,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently modified their holdings of the business. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S during the second quarter valued at about $25,000. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at approximately $42,000. Albion Financial Group UT increased its holdings in Novo Nordisk A/S by 121.4% in the 4th quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Finally, Carolina Wealth Advisors LLC bought a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $48,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of a number of analyst reports. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets lowered their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Up 1.0 %

Shares of NVO opened at $81.36 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business has a fifty day moving average of $96.10 and a 200 day moving average of $115.79. The company has a market cap of $365.09 billion, a PE ratio of 26.33, a P/E/G ratio of 0.89 and a beta of 0.45. Novo Nordisk A/S has a 52-week low of $78.17 and a 52-week high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.